Patients on exchange plans are more likely to see higher out-of-pocket costs for their specialty drugs in 2015 compared with 2014, according to a new analysis from Avalere Health.
Patients on exchange plans are more likely to see higher out-of-pocket costs for their specialty drugs in 2015 compared with 2014, according to a new analysis from Avalere Health.
Plans charging coinsurance greater than 30% for specialty medications for life-threatening illnesses such as cancer, rheumatoid arthritis, or multiple sclerosis, has increased to 41% of silver plans in 2015 from just 27% in 2014. Overall, approximately two-thirds of individuals on the exchanges picked silver plans in 2014 and 28% of exchange enrollees are between the ages of 18 and 34 years.
“Health plans continue to focus on managing drug costs to keep premiums low,” Dan Mendelson, chief executive officer at Avalere Health, said in a statement. “Competitive premiums are key to a sustainable exchange marketplace, which has led plans to pursue more significant cost-sharing. In some cases this could make it difficult for patients to afford and stay on medications.”
More than half (52%) of bronze plans are charging a coinsurance above 30% for specialty tier drugs in 2015 (up from 38% in 2014), while 26% of platinum plans are doing so (up from 17% in 2014). Gold plans are the least likely to be picked.
A total of 80% of silver plans, 91% of bronze plans, 80% of gold, and 66% of platinum plans charge any coinsurance for cost sharing on the specialty tier, Avalere reported. Overall, 63% of plans use coinsurance for specialty drugs.
According to Caroline Pearson, vice president at Avalere, coinsurance can make medication costs unpredictable for consumers, and from year to year the changes in cost-sharing requirements can surprise patients who are medication depedent.
“As a result, consumers who rely on specialty drugs should make sure they are evaluating their plan options in 2015,” she said. “In particular, some patients may be better off paying more in monthly premiums in exchange for lower out-of-pocket costs.”
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen